Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B

Thrombosis and Haemostasis

Volumn 79, Issue 2, 1998, Pages 371-377

  Hosaka, Yoshitaka ^a   Takahashi, Yasuo ^a   Ishii, Hidemi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CARBOXYPEPTIDASE B; IMMUNOGLOBULIN G ANTIBODY; PLASMIN; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; HUMAN CELL; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL;

EID: 0031935464     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614994     Document Type: Article

References (35)

1. Ishii H. The detection and measurement of thrombomodulin. In: Thrombin, Thrombomodulin and the Control of Hemostasis. Giddings JC, eds. RG Landes Company, Austin, TX 1994; pp 121-41.
2. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
3. Horie S, Ishii H, Hara H, Kazama M. Enhancement of thrombin-thrombomodulin-catalyzed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids: possible physiological significance of phosphatidylethanolamine in anticoagulant activity of thrombomodulin. Biochem J 1994; 301: 683-91.
4. Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6: 1891-7.
5. Wen D, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE. Human thrombomodulin: Complete cDNA sequence and chromosome localization of the gene. Biochemistry 1987; 26: 4350-7.
6. Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989; 264: 10351-3.
7. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 1992; 267: 6164-70.
8. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76: 2178-81.
9. Ishii H, Nakano M, Tsubouchi J, Ishikawa T, Uchiyama H, Hiraishi S, Tahara C, Miyajima Y, Kazama M. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemost 1990; 63: 157-62.
10. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endotheliai cells. Thromb Haemost 1991; 65: 618-23.
11. Conway EM, Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. Blood 1993; 81: 726-33.
12. Yamamoto S, Mizoguchi T, Tamaki T, Ohkuchi M, Kimura S, Aoki N. Urinary thrombomodulin, its isolation and characterization. J Biochem 1993; 113: 433-40.
13. Jackson DE, Tetaz TJ, Salem HH, Mitchell CA. Purification and characterization of two forms of soluble thrombomodulin from human urine. Eur J Biochem 1994; 221: 1079-87.
14. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-9.
15. Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991; 37: 269-72.
16. Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, Ishii H, Kazama M, Makino I. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 1990; 39: 983-88.
17. 2-plasmin inhibitor-plasmin complex are elevated in active systemic lupus erythematosus. J Reumatol 1992; 19: 1704-9.
18. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
19. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
20. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
21. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
22. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
23. Bajzar L, Fredenburgh JC, Nesheim M. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem 1990; 265: 16948-54.
24. Levin Y, Skidgel RA, Erdos EG. Isolation and characterization of the subunits of human plasma carboxypeptidase N (kininase I). Proc Natl Acad Sci USA 1982; 79: 4618-22.
25. Ryan CA. Purification and properties of a carboxypeptidase inhibitor from potatoes. J Biol Chem 1974; 249: 5495-9.
26. Mckay TJ, Plummer TH Jr. By-product analogues for bovine carboxypeptidase B. Biochemistry 1978; 17: 401-5.
27. Tanaka T, Suda H, Naganawa H, Hamada M, Takeuchi T, Aoyagi T, Umezawa H. Production of (s)-α-benzylmalic acid, inhibitor of carboxypeptidase a by actinomycetes. J Antibiotics 1984; 37: 682-4.
28. Ogawa K, Iimura H, Aoyagi H, Takeuchi T, Moriguchi T, Umeda Y. Histargin: a novel carboxypeptidase B inhibitor, in Katsumura N, Kominami E (ed): Intracellular proteolysis-mechanisms and regulation. Tokyo, Japan Scientific Societies Press. 1989; p 412-3.
29. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
30. Rubin RN, Colman RW. Disseminated intravascular coagulation. Drugs 1992; 44: 963-71.
31. Giles AR. Disseminated intravascular coagulation. In: Haemostasis and Thrombosis. vol 2. Bloom AR, Forbes CD, Thomas DD, Tuddenham EGD, eds. Churchill Livingstone, Edinburgh, UK. 1994; pp 969-86.
32. Takahashi Y, Hosaka Y, Niina H, Nagasawa K, Naotsuka M, Sakai K, Uemura A. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo. Thromb Haemost 1995; 73: 805-11.
33. Takahashi Y, Hosaka Y, Imada K, Adachi T, Niina H, Watanabe M, Mochizuki H. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: Comparison with low molecular weight heparin. Thromb Haemost 1997; 77: 789-95.
34. Okajima K, Abe H, Binder BR. Endothelial cell injury induced by plasmin in vitro. J Lab Clin Med 1995; 126: 377-84.
35. de Munk GAW, Groeneveld E, Rijken DC. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (prourokinase) by thrombomodulin. J Clin Invest 1991; 88: 1680-4.